June 4, 2024 ASCO 2024: Efficacy and safety of the vebreltinib in previously treated, IDH mutant high-grade glioma patients with PTPRZ1-MET FUsion GENe (FUGEN): a randomized, multicentre, open-label, phase II/III trial 1.4 MB June 4, 2024 ASCO 2024: Efficacy and Safety of Vebreltinib in Patients With Advanced NSCLC Harboring Met-Exon 14-Skipping: Results of 2.5 Year Follow-Up in KUNPENG 1.2 MB April 10, 2024 AACR Annual Meeting 2024: Dependence of EGFR-mutant NSCLC on MET as demonstrated by vebreltinib, a novel and selective brain-penetrating MET kinase inhibitor 647.5 KB April 10, 2024 AACR Annual Meeting 2024: Vebreltinib: A novel brain-penetrating MET kinase inhibitor demonstrates the mechanism of action and pharmacological anti-tumor activity in diverse patient-derived MET-dysregulated tumor models at clinically relevant drug levels 1.6 MB December 4, 2023 2023 IASLC North America Conference on Lung Cancer, December 2023 poster presentation (Vebreltinib Efficacy In METex14 Mutant NSCLC With or Without Concurrent MET Amplification, MET GCN Status Distributions Compared With Public Databases) 399.3 KB October 26, 2023 ESMO 2023 oral presentation (Target therapy matched to genomic alterations in patients with recurrent IDH wildtype glioblastoma: a real-life cohort analysis from Veneto Institute of Oncology, Padua, Italy) 3 MB October 23, 2023 ESMO 2023 poster presentation (Preliminary Results of Phase II KUNPENG Study of Vebreltinib in Patients (Pts) with Advanced NSCLC Harboring c-MET Alterations) 346.3 KB September 15, 2023 IASLC 2023 World Conference on Lung Cancer, September 2023 poster presentation 549.7 KB April 14, 2023 The 23rd Annual R. Bryan Miller Symposium 5.4 MB
ASCO 2024: Efficacy and safety of the vebreltinib in previously treated, IDH mutant high-grade glioma patients with PTPRZ1-MET FUsion GENe (FUGEN): a randomized, multicentre, open-label, phase II/III trial 1.4 MB
ASCO 2024: Efficacy and Safety of Vebreltinib in Patients With Advanced NSCLC Harboring Met-Exon 14-Skipping: Results of 2.5 Year Follow-Up in KUNPENG 1.2 MB
AACR Annual Meeting 2024: Dependence of EGFR-mutant NSCLC on MET as demonstrated by vebreltinib, a novel and selective brain-penetrating MET kinase inhibitor 647.5 KB
AACR Annual Meeting 2024: Vebreltinib: A novel brain-penetrating MET kinase inhibitor demonstrates the mechanism of action and pharmacological anti-tumor activity in diverse patient-derived MET-dysregulated tumor models at clinically relevant drug levels 1.6 MB
2023 IASLC North America Conference on Lung Cancer, December 2023 poster presentation (Vebreltinib Efficacy In METex14 Mutant NSCLC With or Without Concurrent MET Amplification, MET GCN Status Distributions Compared With Public Databases) 399.3 KB
ESMO 2023 oral presentation (Target therapy matched to genomic alterations in patients with recurrent IDH wildtype glioblastoma: a real-life cohort analysis from Veneto Institute of Oncology, Padua, Italy) 3 MB
ESMO 2023 poster presentation (Preliminary Results of Phase II KUNPENG Study of Vebreltinib in Patients (Pts) with Advanced NSCLC Harboring c-MET Alterations) 346.3 KB